Prevention of hematomas in the induction of injection cosmetology interventions
- Authors: Zhuchkov M.V.1, Bolshakova E.E.1, Sonin D.B.1, Zhuchkova U.V.2
-
Affiliations:
- Regional Clinical Skin and Venereal Disease Dispensary
- City Clinical Emergency Hospital Dzerzhinskogo str., 11, Ryazan, 390013
- Issue: Vol 94, No 6 (2018)
- Pages: 31-36
- Section: CLINICAL PRACTICE GUIDELINES
- URL: https://journals.rcsi.science/0042-4609/article/view/116968
- DOI: https://doi.org/10.25208/0042-4609-2018-94-6-31-36
- ID: 116968
Cite item
Full Text
Abstract
The aim of the study was to assess the preventive efficacy of using topical brimonidine tartrate in individuals who underwent cosmetic cosmetology injections in terms of reducing the risk of skin hematoma formation at injection sites.
Materials and methods. The study included 296 patients; the average age of patients in the study was 36.3 ± 7.4 years. The criterion for the inclusion of patients in the study was either the presence of indications for the use of botulinum toxin type A drugs, or fillers. Patients were divided into groups of preventive use of topical brimonidine tartrate and a control group. The evaluation was carried out to achieve the end for patients — the onset of an episode of hemorrhagic complication of the injection procedure.
Results and conclusions. The study demonstrated a reduction in the risk of hemorrhagic complications in patients who underwent contour plastic with previous preventive prescription of topical brimonidine tartrate.
About the authors
M. V. Zhuchkov
Regional Clinical Skin and Venereal Disease Dispensary
Author for correspondence.
Email: misha.juchkov@gmail.com
Cand. Sci. (Med.), Chief Dermatovenereologist and Cosmetologist of the Ministry of Health of the Ryazan Region, Deputy Chief Physician,
Sportivnaya str., 9, Ryazan, 390046
Russian FederationE. E. Bolshakova
Regional Clinical Skin and Venereal Disease Dispensary
Email: fake@neicon.ru
Head Doctor, Chairman of the Ryazan Regional Branch “RODVK”,
Sportivnaya str., 9, Ryazan, 390046
Russian FederationD. B. Sonin
Regional Clinical Skin and Venereal Disease Dispensary
Email: fake@neicon.ru
Cand. Sci. (Med.), Deputy Head Doctor of the Regional Clinical Skin and Venereal Diseases Clinic of the Regional Clinical Hospital,
Sportivnaya str., 9, Ryazan, 390046
Russian FederationU. V. Zhuchkova
City Clinical Emergency HospitalDzerzhinskogo str., 11, Ryazan, 390013
Email: fake@neicon.ru
Cand. Sci. (Med.), surgeon of the Regional Clinical Hospital Emergency Clinical Hospital
Dzerzhinskogo str., 11, Ryazan, 390013
Russian FederationReferences
- Cambridge D. UK-14,304, a potent and selective alpha2-agonist for the characterisation of alpha-adrenoceptor subtypes. Eur J Pharmacol. 1981;72(4):413–415.
- Gómez-Aguayo F., Paczka J. A., Leñero-Córdova R., JiménezRomán J., Davila-Villarreal J., Hartleben C. et al. A Phase III Randomized Clinical Trial of a 0.5 % Timolol + 0.2 % Brimonidine + 2.0 % Dorzolamide Fixed Combination, Preservative-Free Ophthalmic Solution vs. 0.5 % Timolol + 0.2 % Brimonidine + 2.0 % Dorzolamide Fixed Combination in Patients with Controlled Primary Open-Angle Glaucoma. Ophthalmol Ther. 2018;7(1):145–146.
- Fowler J., Jarratt M., Moore A., Meadows K., Pollack A., Steinhoff M. et al. Once-daily topical brimonidine tartrate gel 0,5 % is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol. 2012;166(3):633–641.
- Gold L. S., Papp K., Lynde C., Lain E., Gooderham M., Johnson S. et al. Treatment of Rosacea with Concomitant Use of Topical Ivermectin 1 % Cream and Brimonidine 0.33 % Gel: A Randomized, Vehiclecontrolled Study. J Drugs Dermatol. 2017;16(9):909–916.
- Klein A. W. Complications and adverse reactions with the use of botulinum toxin. Semin Cutan Med Surg. 2001;20(2):109–120.
- Lowe P. L., Patnaik R., Lowe N. J. A comparison of two botulinum type a toxin preparations for the treatment of glabellar lines: double-blind, randomized, pilot study. Dermatol Surg. 2005;31(12):1651–1654.
- Wollina U., Konrad H. Managing adverse events associated with botulinum toxin type A: a focus on cosmetic procedures. Am J Clin Dermatol. 2005;6(3):141–145.
Supplementary files
